The CAS registry number for BPC-157 is 137525-51-0
The compound does not appear to have carcinogenic activity in the models tested, and its interaction with tumor biology, a legitimate concern given that angiogenesis also supports tumor vascularization, has been examined in several studies without evidence of tumor promotion at physiological doses
Vitamin B12 IV Drip for Cellular Rejuvenation For individuals who want rapid replenishment of Vitamin B12, an IV Drip is another effective option
Retatrutides prescription availability in Canada is projected to follow Phase 3 trial completion and regulatory review, likely beginning in 2026 at the earliest
An immune boosting vitamin is no replacement for a vaccine they're not even in the same ballpark when it comes to preventing serious illness, says Hancock
in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding it to the final 503A bulks list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk